- Issuer ticker
-
TSBX
- Reported as of
-
25 Jul 2023
- Net transaction value
-
$0
Source evidence
Original filing metadata and source links for verification.
5 source fields
- SEC form
-
4
- Accepted by SEC
-
27 Jul 2023, 08:42:15 UTC
Reporting owner
1 detail
- Reporting owner signature
-
Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson
Key filing fact
FMR LLC filed Form 4 for Turnstone Biologics Corp. (TSBX) on 27 Jul 2023.
Key facts
- This page summarizes FMR LLC's Form 4 filing for Turnstone Biologics Corp. (TSBX).
- 12 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 27 Jul 2023, 08:42.
Change
- Previous filing in this sequence was filed on 20 Jul 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TSBX
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +91,663
- Change %
- Price
-
- Shares after
- 91,663
- Date
- 25 Jul 2023
- Ownership
- F-Prime Capital Partners Healthcare Fund V LP
- Footnotes
- F1
TSBX
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +106,496
- Change %
- +116%
- Price
-
- Shares after
- 198,159
- Date
- 25 Jul 2023
- Ownership
- F-Prime Capital Partners Healthcare Fund V LP
- Footnotes
- F1
TSBX
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +150,809
- Change %
- +76%
- Price
-
- Shares after
- 348,968
- Date
- 25 Jul 2023
- Ownership
- F-Prime Capital Partners Healthcare Fund V LP
- Footnotes
- F1
TSBX
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +483,684
- Change %
- +139%
- Price
-
- Shares after
- 832,652
- Date
- 25 Jul 2023
- Ownership
- F-Prime Capital Partners Healthcare Fund V LP
- Footnotes
- F1
TSBX
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +296,396
- Change %
- Price
-
- Shares after
- 296,396
- Date
- 25 Jul 2023
- Ownership
- Impresa Fund III Limited Partnership
- Footnotes
- F1
TSBX
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +4,939
- Change %
- Price
-
- Shares after
- 4,939
- Date
- 25 Jul 2023
- Ownership
- F-Prime Capital Partners Healthcare Advisors Fund V LP
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TSBX
transaction
Derivative
Series D Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -91,663
- Change %
- -100%
- Price
-
- Shares after
- 0
- Date
- 25 Jul 2023
- Ownership
- F-Prime Capital Partners Healthcare Fund V LP
- Underlying class
- Common Stock
- Underlying amount
- 91,663
- Exercise price
- Footnotes
- F1
TSBX
transaction
Derivative
Series C Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -106,496
- Change %
- -100%
- Price
-
- Shares after
- 0
- Date
- 25 Jul 2023
- Ownership
- F-Prime Capital Partners Healthcare Fund V LP
- Underlying class
- Common Stock
- Underlying amount
- 106,496
- Exercise price
- Footnotes
- F1
TSBX
transaction
Derivative
Series B-2 Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -150,809
- Change %
- -100%
- Price
-
- Shares after
- 0
- Date
- 25 Jul 2023
- Ownership
- F-Prime Capital Partners Healthcare Fund V LP
- Underlying class
- Common Stock
- Underlying amount
- 150,809
- Exercise price
- Footnotes
- F1
TSBX
transaction
Derivative
Series B-1 Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -483,684
- Change %
- -100%
- Price
-
- Shares after
- 0
- Date
- 25 Jul 2023
- Ownership
- F-Prime Capital Partners Healthcare Fund V LP
- Underlying class
- Common Stock
- Underlying amount
- 483,684
- Exercise price
- Footnotes
- F1
TSBX
transaction
Derivative
Series B-2 Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -296,396
- Change %
- -100%
- Price
-
- Shares after
- 0
- Date
- 25 Jul 2023
- Ownership
- Impresa Fund III Limited Partnership
- Underlying class
- Common Stock
- Underlying amount
- 296,396
- Exercise price
- Footnotes
- F1
TSBX
transaction
Derivative
Series B-2 Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -4,939
- Change %
- -100%
- Price
-
- Shares after
- 0
- Date
- 25 Jul 2023
- Ownership
- F-Prime Capital Partners Healthcare Advisors Fund V LP
- Underlying class
- Common Stock
- Underlying amount
- 4,939
- Exercise price
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Explanation of responses
1 footnote
SEC remarks
Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: The general partner of F-Prime Capital Partners Healthcare Fund V LP is F-Prime Capital Partners Healthcare Advisors Fund V LP (FPCPHA). FPCPHA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.